Satanic FDA makes FMT treatment less accessible
Gut bacteria holds all the cures, and these satanic fucks just made it harder to get. FDA still controlled by Big Pharma. Speaking directly to you, RFK JR, this WILL be changed. I WILL have my epilepsy cured. NO MORE BULLSHIT.
The FDA has not outright removed the ability to receive fecal microbiota transplantation (FMT) treatment, but recent regulatory changes have made access more restricted.
Previously, the FDA exercised "enforcement discretion," allowing healthcare providers to administer FMT for recurrent Clostridioides difficile (C. diff) infections without requiring an Investigational New Drug (IND) application. However, this policy ended in late 2024. Now, to administer FMT, providers must obtain an IND, aligning FMT with the regulatory standards of investigational drugs
Peggy Lillis Foundation
.
This shift has impacted organizations like OpenBiome, the largest U.S. stool bank, which suspended its FMT distribution after October 31, 2024, due to challenges in submitting a commercial IND
Peggy Lillis Foundation
. While institutions like the University of Minnesota continue FMT under their own INDs, the overall availability of FMT has decreased.
Although the FDA has approved microbiome-based therapies such as Rebyota™ and Vowst™ for recurrent C. diff infections, these treatments are not indicated for certain populations, including pediatric patients and those with severe or fulminant disease
Peggy Lillis Foundation
. As a result, FMT remains a critical option for these vulnerable groups.
Advocacy groups like the American Gastroenterological Association are urging the FDA to maintain access to conventional FMT for patients who cannot benefit from the newly approved therapies .
Peggy Lillis Foundation
+2
Gastroenterology.com
+2
Medscape
+2
If you or someone you know is affected by these changes, consider reaching out to the FDA at ocod@fda.hhs.gov or cberombudsman@fda.hhs.gov to share your perspective.